hackint0sh/New-Dataset huggingface dataset:
Following the CAR-T cell infusion, patients will be subjected to rigorous monitoring to assess safety and treatment response. primaryPurpose: TREATMENT masking: NONE maskingDescription: Open-label clinical trials are a category of clinical research where the masking is minimal or nonexistent. In such trials, both the participants and the researchers are fully aware of the treatment assignments, which means participants know the treatment they are receiving, and researchers are aware of each participant's treatment group. count: 75 type: ESTIMATED name: CD19- BCMA CAR-T cells measure: Incidence and severity of dose limiting toxicities (DLTs) following chemotherapy preparative regimen and infusion of CD19/BCMA chimeric antigen receptor (CAR) T cells measure: Rate of successful manufacture and expansion of the CD19/BCMA chimeric antigen receptor (CAR) T cells sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: District one hospital city: Shanghai country: China lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06350097 id: D516NC00001 briefTitle: Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer acronym: TROPION-Lung14 overallStatus: NOT_YET_RECRUITING date: 2024-05-16 date: 2028-03-21 date: 2032-05-25 date: 2024-04-05 date: 2024-04-10 name: AstraZeneca class: INDUSTRY name: Daiichi Sankyo briefSummary: The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Datopotamab Deruxtecan (i.v. infusion) compared with osimertinib (tablet) monotherapy as a first-line therapy in participants with locally advanced or metastatic EGFRm (Ex19del and/or L858R) NSCLC.
nctId: NCT06350084 id: 2023/381 briefTitle: Effect of Mother's Touch and Nurse's Therapeutic Touch on Pain Level and Crying Time During Heel Blood Collection overallStatus: RECRUITING date: 2023-09-04 date: 2024-07-31 date: 2024-12-31 date: 2024-04-05 date: 2024-04-08 name: Burdur Mehmet Akif Ersoy University class: OTHER briefSummary: This prospective study is planned as a randomized controlled study with the purpose of determining the effect of Mother's Touch and Nurse's Therapeutic Touch on pain levels and crying times by newborns during heel blood collection. conditions: Pain, Acute conditions: Newborn conditions: Crying studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 120 type: ESTIMATED name: Mother's Touch name: Nurse's Therapeutic Touch measure: NIPS (Neonatal Infant Pain Scale) measure: Crying times measure: Processing time sex: ALL minimumAge: 2 Days maximumAge: 4 Days stdAges: CHILD facility: Burdur Bucak State Hospital status: RECRUITING city: Burdur state: Bucak zip: 15030 country: Turkey name: Selda Ateş Beşirik, PhD. role: CONTACT phone: +905076228189 email: seldaates07@gmail.com name: Selda Ateş Beşirik, PhD. role: PRINCIPAL_INVESTIGATOR name: Emine Geçkil, Prof. role: SUB_INVESTIGATOR lat: 37.72028 lon: 30.29083 hasResults: False
nctId: NCT06350071 id: 2023/06 briefTitle: Effect of Kangaroo Care and Swaddling Methods on Pain Level and Crying Time During Heel Blood Collection overallStatus: RECRUITING date: 2023-06-19 date: 2024-07-31 date: 2024-12-31 date: 2024-04-05 date: 2024-04-08 name: Burdur Mehmet Akif Ersoy University class: OTHER briefSummary: This prospective study is planned as a randomized controlled study with the purpose of determining the effect of kangaroo care and swaddling methods on pain levels and crying times by newborns during heel blood collection. conditions: Pain, Acute conditions: Newborns conditions: Crying studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 120 type: ESTIMATED name: Kangaroo Care name: Swaddling measure: NIPS (Neonatal Infant Pain Scale) measure: Crying times measure: Processing time sex: ALL minimumAge: 1 Day maximumAge: 4 Days stdAges: CHILD facility: Burdur Bucak State Hospital status: RECRUITING city: Burdur state: Bucak zip: 15030 country: Turkey name: Selda Ateş Beşirik, PhD. role: CONTACT phone: +905076228189 email: seldaates07@gmail.com name: Selda Ateş Beşirik, PhD. role: PRINCIPAL_INVESTIGATOR name: Emine Geçkil, Prof. role: SUB_INVESTIGATOR lat: 37.72028 lon: 30.29083 hasResults: False
nctId: NCT06350058 id: 202012005 briefTitle: Phase I Clinical Trial of Inactivated Rotavirus Vaccine in a Population Aged 6 Weeks-49 Years Old overallStatus: ACTIVE_NOT_RECRUITING date: 2021-08-03 date: 2023-11-30 date: 2024-10-31 date: 2024-04-05 date: 2024-04-05 name: Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd class: INDUSTRY briefSummary: The research objective is to evaluate the safety and tolerability of the inactivated rotavirus vaccine and explore its preliminary immunogenicity. conditions: Healthy Volunteers studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 375 type: ACTUAL name: Inactivated rotavirus vaccine (low dose) name: Inactivated rotavirus vaccine (high dose) name: Placebo measure: Incidence rate of AE measure: Incidence rate of SAE sex: ALL minimumAge: 6 Weeks maximumAge: 49 Years stdAges: CHILD stdAges: ADULT facility: Hebei Provincial Center for Disease Control and Prevention city: Shijiangzhuang state: Hebei zip: 050021 country: China lat: 34.61038 lon: 113.58554 hasResults: False
nctId: NCT06350045 id: supra 11th puncture PCNL briefTitle: High Supracostal Versus Subcostal Puncture in Adult PCNL overallStatus: ACTIVE_NOT_RECRUITING date: 2024-03-01 date: 2028-04-01 date: 2028-04-01 date: 2024-04-05 date: 2024-04-05 name: Assiut University class: OTHER briefSummary: as the supra eleventh puncture PCNL is not well investigated in the literature we will conduct that randomised trial in comparison to the subcostal one conditions: Urolithiasis studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: closed envelop whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 162 type: ACTUAL name: PCNL measure: Rate of complications measure: Stone free rate measure: duration of Hospital stay. measure: Operative time sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Assiut University Hospital city: Assiut zip: 11751 country: Egypt lat: 27.18096 lon: 31.18368 hasResults: False
nctId: NCT06350032 id: TREPaed id: 2023-505082-91-00 type: CTIS briefTitle: Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAH overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2028-11 date: 2028-11 date: 2024-04-05 date: 2024-04-05 name: AOP Orphan Pharmaceuticals AG class: INDUSTRY briefSummary: The goal of this clinical trial is to evaluate safety and tolerability of preservative-free parenteral treprostinil in paediatric patients with PAH (PH Group 1) who are below 18 years of age. The main question it aims to answer is:
Participants will receive either subcutaneous (SC) or intravenous (IV) preservative-free treprostinil and will be observed for 5 months (20 weeks ± 1 week). conditions: Pulmonary Arterial Hypertension studyType: INTERVENTIONAL phases: PHASE3 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: preservative-free parenteral treprostinil measure: Frequency and seriousness of adverse events and adverse drug reactions measure: Change from baseline in quality of Life (QoL) measure: Change from baseline in 6-minute walk distance (6MWD) measure: Change from baseline in World Health Organization Functional Class (WHO FC) measure: Change from baseline in echocardiography (ECHO) parameters - RA/RV enlargement measure: Change from baseline in echocardiography (ECHO) parameters - RV systolic dysfunction measure: Change from baseline in echocardiography (ECHO) parameters - RV/LV end-systolic ratio (PSAX) measure: Change from baseline in echocardiography (ECHO) parameters - tricuspid annular plane systolic excursion (TAPSE) measure: Change from baseline in echocardiography (ECHO) parameters - S/D ratio (TR jet) measure: Change from baseline in echocardiography (ECHO) parameters - Pulmonary Artery Acceleration Time (PAAT) measure: Change from baseline in echocardiography (ECHO) parameters - pericardial effusion measure: Change from baseline in echocardiography (ECHO) parameters - eccentricity index measure: Change from baseline in echocardiography (ECHO) parameters - acceleration time measure: Change from baseline in plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) levels measure: Treprostinil plasma concentration sex: ALL maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Medizinische Universität Wien city: Vienna zip: 1090 country: Austria name: Sulaimi Albinni, MD role: PRINCIPAL_INVESTIGATOR lat: 48.20849 lon: 16.37208 facility: Necker-Enfants Malades Hospital, Paris city: Paris zip: 75015 country: France name: Damien Bonnet, Prof role: PRINCIPAL_INVESTIGATOR lat: 48.85341 lon: 2.3488 facility: Gottsegen National Cardiovascular Center city: Budapest zip: H-1096 country: Hungary name: Laszlo Ablonczy, MD role: PRINCIPAL_INVESTIGATOR lat: 47.49801 lon: 19.03991 facility: Ramón y Cajal University Hospital city: Madrid zip: 28034 country: Spain name: Maria J del Cerro, Prof role: PRINCIPAL_INVESTIGATOR lat: 40.4165 lon: -3.70256 hasResults: False
nctId: NCT06350019 id: 26379996/91 briefTitle: Vascular Effects of Penil revascularızatıon overallStatus: COMPLETED date: 2013-01-01 date: 2014-08-15 date: 2014-12-25 date: 2024-04-05 date: 2024-04-05 name: Ankara Yildirim Beyazıt University class: OTHER briefSummary: Purpose: The aim of this study is to measure the effects of penile revascularization surgery performed in vascular origin erectile dysfunction (ED) on penile vascular hemodynamic and to determine the importance of vascular parameters in postoperative patient follow-up.
Methods: A total of 35 participants who underwent penile revascularization surgery due to vascular ED were included in this study. In the preoperative period and at the 3rd postoperative month, penile color doppler ultrasonography (PCDU) was performed to evaluate cavernosal arteries, dorsal arteries, deep dorsal vein and inferior epigastric artery (IEA) separately. During this evaluation, peak systolic velocity (PSV), end diastolic velocity (EDV), and resistive index (RI) were measured. The International Index of Erectile Function questionnaire (IIEF) was applied to all patients in the preoperative period and at the 3rd postoperative month. The relationship between changes in (IIEF) questionnaire score and penile vascular hemodynamic changes in the postoperative period was evaluated. conditions: Erectile Dysfunction conditions: Erectile Dysfunction Due to Arterial Disease conditions: Erectile Dysfunction Due to Venous Disorder studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 35 type: ACTUAL name: Penile revascularızation measure: The importance of resistive index in evaluating the postoperative success of penile revascularization sex: MALE minimumAge: 23 Years maximumAge: 69 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06350006 id: SHR-A1904-301 briefTitle: SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor overallStatus: RECRUITING date: 2024-05-30 date: 2027-12-30 date: 2028-12-30 date: 2024-04-05 date: 2024-04-26 name: Shanghai Hengrui Pharmaceutical Co., Ltd. class: INDUSTRY briefSummary: This study consists of two research phases:
Phase III: A randomized, double-blind, multicenter clinical study of SHR-1904 combined with chemotherapy and immunotherapy Versus chemotherapy combined with immunotherapy for CLDN18.2-positive advanced solid tumors. conditions: Cldn18.2-positive Advanced Solid Tumor studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This study is a multicenter Phase Ib/III clinical study. Phase Ib consists of two phases, IB-A for dose escalation and IB-B for efficacy extension. The Phase III multi-center, randomized controlled, double-blind study was designed to evaluate the efficacy and safety of SHR-A1904 combined chemotherapy and immunotherapy versus chemotherapy combined immunotherapy in first-line treatment of CLDN18.2-positive solid tumors patients. primaryPurpose: TREATMENT masking: NONE count: 924 type: ESTIMATED name: SHR-A1904; Adebrelimab name: SHR-A1904; CAPOX; Adebrelimab measure: Incidence and severity of AE measure: Dose Limiting Toxicity (DLT) measure: Maximal Tolerable Dose (MTD) measure: Phase III Recommended Dose (RP3D) measure: Progression-free survival (PFS) assessed by blind Independent Center Review (BICR) based on RECIST 1.1 criteria measure: SHR-A1904 toxin binding antibody measure: SHR-A1904 Total antibody measure: Immunogenicity indicators of SHR-A1904: drug resistant antibody (ADA) and neutralizing antibody (NAb) measure: Expression level of CLDN18.2 in tumor tissues measure: Overall survival (OS) measure: Incidence and severity of AE sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sun Yat-sen University Cancer Center status: RECRUITING city: Guangzhou state: Guangdong zip: 510060 country: China name: Ruihua Xu role: CONTACT lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06349993 id: pd003 briefTitle: Digital Intervention for Depression and Anxiety in Adolescents overallStatus: RECRUITING date: 2024-04-17 date: 2024-12-30 date: 2025-07-01 date: 2024-04-05 date: 2024-04-22 name: Adai Technology (Beijing) Co., Ltd. class: OTHER briefSummary: The goal of this clinical trial is to evaluate the effectiveness of digital interventions in treating depression and anxiety in adolescents. The main question it aims to answer is: Can digital interventions effectively alleviate symptoms of depression and anxiety in adolescents? The trial will include a comparison group where researchers will compare the effects of the digital intervention to traditional health education methods to assess their relative efficacy.
Participants will be asked to engage with the digital intervention platform for a period of two months. conditions: Depression conditions: Anxiety studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 100 type: ESTIMATED name: Digital Intervention name: Health Education measure: Hamilton Depression Rating Scale measure: Hamilton Anxiety Rating Scale measure: ADHD(attention deficit hyperactivity disorder) Rating Scale-IV measure: PHQ-9 (Patient Health Questionnaire-9) measure: GAD-7 (Generalized Anxiety Disorder-7) sex: ALL minimumAge: 10 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: West China Hospital status: RECRUITING city: Chengdu state: Sichuang country: China name: Liqun Zhang role: CONTACT lat: 30.66667 lon: 104.06667 hasResults: False
nctId: NCT06349980 id: HLX53-HCC201 briefTitle: A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 With or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients. overallStatus: NOT_YET_RECRUITING date: 2024-05-10 date: 2027-02-10 date: 2027-02-10 date: 2024-04-05 date: 2024-04-09 name: Shanghai Henlius Biotech class: INDUSTRY briefSummary: The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of Serplulimab Injection (HLX10, a Recombinant Anti-PD-1 Antibody) and HLX04 (a Biosimilar to Bevacizumab) With or Without HLX53 (an Anti-TIGIT Fc Fusion Protein) in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients. conditions: Carcinoma, Hepatocellular studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 117 type: ESTIMATED name: HLX53 (1000mg) name: HLX53 (2000mg) name: HLX10 name: HLX04 name: Placebo measure: ORR measure: PFS measure: ORR measure: PFS measure: OS measure: Incidence and severity of adverse events (AEs) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06349967 id: WCH-2023-1592 briefTitle: Nab-paclitaxel Combined With Cadonilimab (AK104) for the Second-line Treatment of Advanced Gastric Cancer overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2027-04-30 date: 2027-05-30 date: 2024-04-05 date: 2024-04-05 name: West China Hospital class: OTHER briefSummary: Currently, standard treatment options for gastric cancer failed to first-line treatment include monotherapy with paclitaxel/irinotecan/docetaxel/albumin paclitaxel, or paclitaxel combined with ramucirumab. However, the efficacy of these regimens is still far from satisfactory. The aim of the study is to evaluate the efficacy and safety of nab-paclitaxel combined with cadonilimab for the second-line treatment of advanced gastric cancer. conditions: Gastric Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 59 type: ESTIMATED name: Nab-paclitaxel Combined With Cadonilimab (AK104) measure: overall response rate (ORR) measure: disease control rate (DCR) measure: overall survival (OS) measure: progression-free survival (PFS) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06349954 id: BFHHZS20240064 briefTitle: Effectiveness and Safety of Single-session Endoscopic Stone Extraction overallStatus: RECRUITING date: 2024-04-15 date: 2024-12-01 date: 2024-12-01 date: 2024-04-05 date: 2024-04-18 name: Beijing Friendship Hospital class: OTHER briefSummary: This is a prospective study, including approximately 64 patients with acute cholangitis accompanied with choledocholithiasis at Beijing Friendship Hospital. All patients will be randomly allocate into single-session or two-session endoscopic stone extraction. The investigators assessed the outcomes of single-session and two-session endoscopic stone extraction. conditions: Choledocholithiasis With Acute Cholangitis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: All patients will be randomly allocated into single-session group or two-session group. primaryPurpose: TREATMENT masking: NONE count: 64 type: ESTIMATED name: single-session ERCP name: two-session ERCP measure: Success rate of complete stone removal measure: ERCP-related complication rate measure: Length of stay measure: Hospital expenses sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing Friendship Hospital status: RECRUITING city: Beijing state: Beijing zip: 100050 country: China name: Wei Jiang role: CONTACT phone: 18663186116 email: jfw899w@outlook.com lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06349941 id: STU-2023-0745 briefTitle: Telemedicine in Rural Patients With Heart Failure acronym: RURAL-HF overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2024-12-01 date: 2024-12-01 date: 2024-04-05 date: 2024-04-05 name: University of Texas Southwestern Medical Center class: OTHER briefSummary: We propose a pilot trial examining the effectiveness of a mHealth-based home cardiac rehabilitation program using a telemedicine platform for the identification, recruitment, and retention of an underserved rural population with heart failure with reduced ejection fraction.(HFrEF). The goal of the pilot trial will be to demonstrate the feasibility of a telemedicine platform for the recruitment and retention of underserved rural patients in clinical trials. Participants will participate in a cardiac rehabilitation program delivered through a smartphone application called Movn. They will be monitored for 14 weeks. conditions: Heart Failure studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Pilot trial primaryPurpose: OTHER masking: NONE count: 100 type: ESTIMATED name: Movn app measure: Physical activity levels measure: Quality of life using KCCQ score measure: Enrollment rate measure: Loss to follow up sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06349928 id: MASF_Dancers01 briefTitle: "The Show Must go on" : The Experience of Injuries Among Dancers: Fears, Thoughts, and Beliefs. A Qualitative Study overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-10-30 date: 2025-04-01 date: 2024-04-05 date: 2024-04-05 name: University of Siena class: OTHER briefSummary: This qualitative, cross-sectional study aims at describing the experience of Italian dancers with injury.
Understanding dancers' thoughts and behaviors regarding past or possible future injuries may be beneficial in improving treatment efficacy and designing adequate education and prevention strategies. It may also help raise awareness of dancers' complex and unique needs, and the importance of having accessible, specialized professionals around dance companies and schools. conditions: Injuries conditions: Dancing conditions: Injury;Sports conditions: Stress, Psychological studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 40 type: ESTIMATED name: Focus group or interview measure: Experience and perception of injury amongst dancers measure: Understanding of injury prevention and pain management amongst dancers sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06349915 id: 2023-15217 briefTitle: A Pilot Evaluation of a Digital Peer Support Intervention for Suicidal Adolescents acronym: SWEEP overallStatus: NOT_YET_RECRUITING date: 2024-09 date: 2026-04 date: 2026-04 date: 2024-04-05 date: 2024-04-05 name: Albert Einstein College of Medicine class: OTHER name: American Foundation for Suicide Prevention name: Yeshiva University briefSummary: Suicide risk has increased among youth in underserved communities, where access to mental healthcare is limited. To address this need, the investigator team plans to evaluate the preliminary efficacy of a brief, low-cost, culturally responsive digital intervention for ethnically diverse youth at risk for suicide in The Bronx, NY. In collaboration with community stakeholders, suicide recovery narratives, featuring adolescents' experiences related to recovery from suicidal thoughts will be developed. A smartphone ecological momentary assessment app will be used to evaluate whether a curriculum of these narratives provides anti-suicidal benefits to at-risk adolescents. conditions: Suicide studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: The first 6 participants will serve as a brief pilot to validate outcomes and the acceptability of the intervention. The study team may make slight changes to the intervention (e.g., time of day the suicide recovery narratives are administered, or which narratives are presented) before recruiting the remaining 40 participants. primaryPurpose: PREVENTION masking: NONE count: 46 type: ESTIMATED name: Supporting Wellbeing with Everyday Experiences of Peers (SWEEP) measure: Suicidal Thoughts measure: Suicidal Urge Resistance measure: Social Connectedness measure: Optimism measure: Social Support measure: Intervention Acceptability measure: Emotions measure: Treatment Readiness sex: ALL minimumAge: 14 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT hasResults: False